1682 related articles for article (PubMed ID: 36519342)
1. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
[TBL] [Abstract][Full Text] [Related]
3. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model.
Li X; Wu S; Du Y; Yang L; Li Y; Hong B
Int J Antimicrob Agents; 2020 Jul; 56(1):106000. PubMed ID: 32360229
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
Tang Y; Zhou H; Xiang Y; Cui F
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of A20 gene in peripheral blood mononuclear cells is associated with the progression of chronic hepatitis B virus infection.
Fan YC; Zhang YY; Sun YY; Wang N; Xiao XY; Wang K
Oncotarget; 2016 Oct; 7(42):68821-68832. PubMed ID: 27634895
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
Shu W; Shanjian C; Jinpiao L; Qishui O
Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase.
Zhan J; Wang J; Zhang Z; Xue R; Jiang S; Liu J; Liu Y; Zhu L; Xia J; Yan X; Ding W; Zhu C; Qiu Y; Li J; Huang R; Wu C
Virulence; 2023 Dec; 14(1):2268497. PubMed ID: 37938933
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-α-induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection.
Liu Y; Jin J; Ji J; Gao XM; Fan YC
Virol J; 2019 Oct; 16(1):120. PubMed ID: 31661000
[TBL] [Abstract][Full Text] [Related]
10. Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project.
Ling Z; Liu X; Cheng Y; Jiang X; Jiang H; Wang Y; Li L
Sci Rep; 2015 Nov; 5():17098. PubMed ID: 26606973
[TBL] [Abstract][Full Text] [Related]
11. Virological response to nucleos(t)ide analogues treatment in chronic hepatitis B patients is associated with Bacteroides-dominant gut microbiome.
Zhang S; Chau HT; Tun HM; Huang FY; Wong DK; Mak LY; Yuen MF; Seto WK
EBioMedicine; 2024 May; 103():105101. PubMed ID: 38583259
[TBL] [Abstract][Full Text] [Related]
12. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B.
Su ZJ; Yu XP; Guo RY; Ming DS; Huang LY; Su ML; Deng Y; Lin ZZ
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):437-44. PubMed ID: 23747030
[TBL] [Abstract][Full Text] [Related]
13. Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.
Wenlin C; Fang L; Yuncheng Z; Jinzhen LV; Daguo Y
J Tradit Chin Med; 2023 Jun; 43(3):559-567. PubMed ID: 37147758
[TBL] [Abstract][Full Text] [Related]
14. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis.
Wang SQ; Shen Y; Li J; Liu Y; Cheng LS; Wu SD; She WM; Jiang W
J Viral Hepat; 2021 May; 28(5):795-808. PubMed ID: 33482039
[TBL] [Abstract][Full Text] [Related]
15. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-β1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis.
Yu X; Guo R; Ming D; Su M; Lin C; Deng Y; Lin Z; Su Z
J Gastroenterol Hepatol; 2014 May; 29(5):1065-72. PubMed ID: 24236690
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes.
Li YN; Kang NL; Jiang JJ; Zhu YY; Liu YR; Zeng DW; Wang F
World J Gastroenterol; 2022 Sep; 28(35):5188-5202. PubMed ID: 36188719
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure.
Wang K; Zhang Z; Mo ZS; Yang XH; Lin BL; Peng L; Xu Y; Lei CY; Zhuang XD; Lu L; Yang RF; Chen T; Gao ZL
Gut Microbes; 2021; 13(1):1-15. PubMed ID: 34006193
[TBL] [Abstract][Full Text] [Related]
18. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
19. Distinct Bile Acid Profiles in Patients With Chronic Hepatitis B Virus Infection Reveal Metabolic Interplay Between Host, Virus and Gut Microbiome.
Sun Z; Huang C; Shi Y; Wang R; Fan J; Yu Y; Zhang Z; Zhu K; Li M; Ni Q; Chen Z; Zheng M; Yang Z
Front Med (Lausanne); 2021; 8():708495. PubMed ID: 34671614
[TBL] [Abstract][Full Text] [Related]
20. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
